Achieving RA Treatment Goals: Real-Word Experience and Emerging Insights into DMARD Monotherapy

Faculty

Neal S. Birnbaum, MD, FACP, MACR
Clinical Professor of Medicine
University of California, San Francisco
Director, Division of Rheumatology
California Pacific Medical Center
San Francisco, California

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
RJ Fasenmyer Chair of Clinical Immunology
Theodore F. Classen, DO Chair of Osteopathic
Research and Education
Vice Chairman, Department of Rheumatic and
Immunologic Diseases
Cleveland, Ohio

Stanley Cohen, MD
Medical Director
Metroplex Clinical Research Center
Clinical Professor of Internal Medicine
University of Texas Southwestern School of Medicine
University of Texas Southwestern Medical School/
Rheumatology Associates
Director, Division of Rheumatology
Presbyterian Hospital
Dallas, Texas

Atul Deodhar, MD
Professor of Medicine
Medical Director, Rheumatology Clinics
Oregon Health & Science University
Portland, Oregon

Nancy E. Lane, MD
Director, Center for Musculoskeletal Health
Endowed Professor of Medicine, Rheumatology
and Aging
University of California at Davis, School of Medicine
Sacramento, California

William F.C. Rigby, MD
Professor of Medicine
Professor of Microbiology and Immunology
Dartmouth Geisel School of Medicine
Lebanon, New Hampshire

Gregg J. Silverman, MD
Professor of Medicine & Pathology
NYU School of Medicine
Professor/Attending
Bellevue Hospital
New York, New York

John Tesser, MD, FACP, FACR
Arizona Arthritis & Rheumatology Associates
Adjunct Assistant Professor
Midwestern University Arizona College of
Osteopathic Medicine
Phoenix, Arizona

Intended Learners

Learning Objectives

After completing this activity, participants should be able to:

• Discuss the impact of recent guidance on the role of monotherapy, sequencing, treat-to-target goals, and new therapies in RA management
• Explore recent real-world data and emerging insights into biologic and non-biologic DMARD monotherapy and the impact on treatment decisions
• Evaluate recent and emerging agents, including JAK inhibitors, and their role in the management of RA
• Develop personized care plans utilizing evidence-based guidance, emerging data, treat-to-target, and shared decision-making strategies